Clinical experts reviewed the features of mpox-related ophthalmic disease and provide management strategies for general practitioners to prevent permanent vision loss. The 2022 global mpox outbreak ...

Patients adherent to SUBLOCADE® for 12 months had 42% lower adjusted non-MOUD medical costs vs. those adherent to other forms of MOUDPatients ...

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers COMMACK, NY, March 11, 2026 ...

The MarketWatch News Department was not involved in the creation of this content. Expands institutional footprint with potential penetration of more than 60% of the U.S. market, while expanding reach ...

Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141 ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

Move comes 2 years after controversial exit of brand-name product ...

Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, ...

The FDA approved a vaccine for mumps nearly 60 years ago, so why are some areas of the United States experiencing outbreaks ...

TONMYA (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults, was commercially launched in November 2025 Treatment with TONMYA provided statistically significant pain ...

Noticing a receding hairline? You’re not alone — and thanks to years of research, effective treatments are within reach. Male ...

When new safety information for medicines is identified, the Therapeutic Goods Administration (TGA) works with the sponsors to update Product ...